The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

EHA 2020 | The relevance of MRD for CLL in the era of targeted therapies

Name: The relevance of MRD for CLL in the era of targeted therapies
Uploaded: 2020-06-02T00:00:00Z
Duration: 1 min 22 s
Description: Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, talks on the relevance of measurable residual disease (MRD) for chronic lymphocytic leukemia (CLL) in the era of targeted therapies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Lydia Scarfò • 2 Jun 2020

EHA 2020

Chronic Lymphocytic Leukemia Leukemia Ibrutinib Venetoclax

CLARITY

Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, talks on the relevance of measurable residual disease (MRD) for chronic lymphocytic leukemia (CLL) in the era of targeted therapies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).